DA Davidson analyst Rudy Kessinger downgrades Telos (NASDAQ:TLS) from Buy to Neutral.
BioAtla Hosting Virtual R&D Day To Highlight BA3071 CAB-CTLA-4 Phase 1 Data In Multiple Solid Tumor Types
Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher dosesOngoing Phase 2 clinical study of monotherapy and in combination